<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02390232</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/14/7319</org_study_id>
    <nct_id>NCT02390232</nct_id>
  </id_info>
  <brief_title>Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH</brief_title>
  <acronym>Coli-NASH</acronym>
  <official_title>Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a population of patients with Non Alcoholic Fatty Liver Disease (NAFLD), the investigators
      will compare the composition of the gut microbiota from patients with simple steatosis with
      that with steatohepatitis.

      The purpose of this study is to determine if the pathogenic Escherichia Coli to the B2 group
      and producing the genotoxin colibactin is a factor for developing NASH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gut microbiota composition is now linked to the onset of obesity, metabolic disorders, and
      Non Alcoholic Fatty Liver Disease . While simple steatosis has benign prognosis,
      steatohepatitis (NASH) leads to cirrhosis and hepatocarcinoma and increases cardiovascular
      and cancer- related mortality. Some Escherichia coli (E. coli) belonging to the B2
      phylogenetic group are involved in many diseases. Those producing the genotoxin colibactin
      are in addition known to induce a chronic alteration of intestinal permeability, one of the
      major factors leading to NASH.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>composition of the gut microbiota between two groups, and prevalence of the Escherichia Coli belonging to the B2 group and producing the genotoxin colibactin.</measure>
    <time_frame>1 day</time_frame>
    <description>compare the composition of the gut microbiota between patients with simple steatosis with steatohepatitis, and determinate the prevalence of the Escherichia Coli belonging to the B2 group and producing the genotoxin colibactin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>differences between the two groups</measure>
    <time_frame>1 day</time_frame>
    <description>highlight other differences between the two cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determine wether bacteria, in particular escherichia Coli can translocate and reach steatohepatitis patients liver</measure>
    <time_frame>1 day</time_frame>
    <description>determine if bacteria, in particular escherichia Coli can translocate and reach steatohepatitis patients liver</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploration of a biomarker of fibrosis from blood microbiota in NAFLD patients</measure>
    <time_frame>1 day</time_frame>
    <description>Determination of bacterial translocation assay PCR 16S bacterial gene in blood and sequence and analyse the microbiota.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>NAFLD with simple steatosis</arm_group_label>
    <description>Patients with NAFLD with simple steatosis: collection of stools, blood sample and liver biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAFLD with steatohepatitis</arm_group_label>
    <description>Patients with NAFLD with steatohepatitis: collection of stools, blood and liver biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>liver biopsy</intervention_name>
    <description>A small needle is inserted into the liver to collect a tissue sample</description>
    <arm_group_label>NAFLD with simple steatosis</arm_group_label>
    <arm_group_label>NAFLD with steatohepatitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>collection of stools</intervention_name>
    <description>collection of stools</description>
    <arm_group_label>NAFLD with simple steatosis</arm_group_label>
    <arm_group_label>NAFLD with steatohepatitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>collection of blood sample</description>
    <arm_group_label>NAFLD with simple steatosis</arm_group_label>
    <arm_group_label>NAFLD with steatohepatitis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      feces, liver, blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Non Alcoholic Fatty Liver Disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NAFLD

          -  indication of liver biopsy

        Exclusion Criteria:

          -  presence of any other cause of liver or steatosis

          -  alcohol consumption exceeding 30 g / day for a men and 20 g / day for a woman

          -  a history of decompensated cirrhosis

          -  treatment with prebiotics, probiotics or antibiotics in the month prior to inclusion

          -  chronic gastrointestinal disease or history of gastrointestinal surgery

          -  pregnancy or breastfeeding

          -  patient under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maeva Guillaume, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Toulouse, h√¥pital Purpan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gut microbiota</keyword>
  <keyword>Non Alcoholic Steato Hepatitis</keyword>
  <keyword>Steatohepatitis</keyword>
  <keyword>Escherichia coli</keyword>
  <keyword>colibactin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

